Scinovex
article Open Access

Evaluation of apo lipoprotein A-1 and some biochemical parameters in the blood of patients with chronic kidney disease

International Journal of Advanced Chemistry Research · 2023 · Vol. 5(1) · pp. 50–54

Abstract

Aim: This study was designed to determine the level of serum Apolipoprotein A-I (ApoA-I), Cystatin C, and homocysteine among three groups - CKD patients without the end-stage renal disease (ESRD), patients with ESRD on hemodialysis and healthy controls. Materials and Methods: A retrospective, hospital-based study was carried out from 100 patients' records from each group, and serum Cystatin-C, homocysteine, apo-A1values were noted. Results: The duration of dialysis treatment was 31 [+ or -] 35 months. Paired t-test analyses showed a significant increase in mean urea and creatinine, uric acid, and Cystatin C among CKD patients which then declined significantly after hemodialysis. Serum Apo-A1 and homocysteine levels were significantly higher in both hemodialysis and pre-dialysis groups compared to control subjects. Conclusion: HD increases apoA1 and Cystatin C whereas decreases HCM and uric acid as both are antagonists that might play a vital role in the pathogenesis of related disorders in CKD Patients.

Folate and B Vitamins ResearchChronic Kidney Disease and DiabetesNutrition and Health in AgingMedicineHomocysteineUric acidCystatin CCreatinineKidney diseaseHemodialysisInternal medicineDialysisRenal function
Citations
0
FWCI
0.00
field-weighted impact
References
0
Percentile
13%
vs. same field & year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Evaluation of apo lipoprotein A-1 and some biochemical parameters in the blood of patients with chronic kidney disease · Scinovex